Total Payments
$12,183
2024 Payments
$1,849
Companies
42
Transactions
764
Medicare Patients
2,385
Medicare Billing
$192,835
Payment Breakdown by Category
Food & Beverage$12,047 (98.9%)
Education$136.07 (1.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $12,047 | 760 | 98.9% |
| Education | $136.07 | 4 | 1.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novo Nordisk Inc | $2,012 | 111 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $1,449 | 59 | $0 (2024) |
| ABBVIE INC. | $1,357 | 127 | $0 (2024) |
| PFIZER INC. | $904.93 | 89 | $0 (2024) |
| Lilly USA, LLC | $798.61 | 56 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $756.14 | 32 | $0 (2024) |
| GlaxoSmithKline, LLC. | $720.96 | 45 | $0 (2024) |
| IRONWOOD PHARMACEUTICALS, INC | $476.53 | 27 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $400.40 | 25 | $0 (2023) |
| Amgen Inc. | $285.21 | 19 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,849 | 115 | AstraZeneca Pharmaceuticals LP ($439.95) |
| 2023 | $1,313 | 93 | Novo Nordisk Inc ($252.29) |
| 2022 | $2,440 | 153 | ABBVIE INC. ($452.84) |
| 2021 | $2,313 | 153 | AbbVie Inc. ($446.75) |
| 2020 | $689.30 | 52 | AstraZeneca Pharmaceuticals LP ($174.37) |
| 2019 | $1,374 | 22 | Novo Nordisk Inc ($405.85) |
| 2018 | $1,266 | 97 | GlaxoSmithKline, LLC. ($204.38) |
| 2017 | $939.20 | 79 | Janssen Pharmaceuticals, Inc ($171.12) |
All Payment Transactions
764 individual payment records from CMS Open Payments — Page 1 of 31
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $14.51 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 12/19/2024 | Exact Sciences Corporation | Cologuard Collection Kit (Device) | Food and Beverage | In-kind items and services | $19.74 | General |
| Category: Oncology | ||||||
| 12/18/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug), XIFAXAN | Food and Beverage | In-kind items and services | $14.78 | General |
| Category: Gastroenterology | ||||||
| 12/18/2024 | Mylan Specialty L.P. | YUPELRI (Drug) | Food and Beverage | In-kind items and services | $14.58 | General |
| Category: Anticholinergics, Inhaled | ||||||
| 12/16/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $14.88 | General |
| Category: PAIN | ||||||
| 12/12/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $20.56 | General |
| Category: Obesity | ||||||
| 12/09/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $18.40 | General |
| Category: Diabetes | ||||||
| 12/04/2024 | PFIZER INC. | ELIQUIS (Drug), NURTEC ODT | Food and Beverage | In-kind items and services | $19.87 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 12/04/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $14.15 | General |
| Category: PAIN | ||||||
| 12/04/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $7.64 | General |
| Category: Diabetes | ||||||
| 12/02/2024 | IRONWOOD PHARMACEUTICALS, INC | Linzess (Drug) | Food and Beverage | Cash or cash equivalent | $16.44 | General |
| Category: GI | ||||||
| 11/22/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $20.76 | General |
| Category: Obesity | ||||||
| 11/19/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $20.23 | General |
| Category: Cardiovascular | ||||||
| 11/19/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $3.67 | General |
| Category: Diabetes | ||||||
| 11/14/2024 | SHIELD THERAPEUTICS INC | ACCRUFER (Drug) | Food and Beverage | In-kind items and services | $18.65 | General |
| Category: Hematology | ||||||
| 11/14/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $3.89 | General |
| Category: PAIN | ||||||
| 11/12/2024 | IRONWOOD PHARMACEUTICALS, INC | Linzess (Drug) | Food and Beverage | Cash or cash equivalent | $21.52 | General |
| Category: GI | ||||||
| 11/12/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $4.37 | General |
| Category: NEUROSCIENCE | ||||||
| 11/08/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $10.05 | General |
| Category: Diabetes | ||||||
| 11/07/2024 | Lilly USA, LLC | MOUNJARO (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $4.22 | General |
| Category: Diabetes | ||||||
| 10/31/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug), TRELEGY ELLIPTA | Food and Beverage | In-kind items and services | $16.20 | General |
| Category: RESPIRATORY | ||||||
| 10/29/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $15.04 | General |
| Category: PAIN | ||||||
| 10/24/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $5.87 | General |
| Category: NEUROSCIENCE | ||||||
| 10/22/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $18.24 | General |
| Category: Obesity | ||||||
| 10/17/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $6.23 | General |
| Category: NEUROSCIENCE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 578 | 819 | $166,036 | $49,310 |
| 2022 | 6 | 618 | 813 | $113,353 | $51,170 |
| 2021 | 7 | 629 | 853 | $109,244 | $54,333 |
| 2020 | 7 | 560 | 812 | $98,243 | $38,023 |
Total Patients
2,385
Total Services
3,297
Medicare Billing
$192,835
Procedure Codes
29
All Medicare Procedures & Services
29 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 176 | 289 | $84,099 | $20,205 | 24.0% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 108 | 108 | $26,460 | $13,190 | 49.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 129 | 210 | $39,384 | $10,765 | 27.3% |
| 90694 | Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | Office | 2023 | 38 | 39 | $6,734 | $2,934 | 43.6% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 39 | 40 | $2,240 | $1,167 | 52.1% |
| 83036 | Hemoglobin a1c level | Office | 2023 | 47 | 80 | $4,240 | $748.44 | 17.7% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 11 | 22 | $1,535 | $150.85 | 9.8% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 12 | 12 | $1,116 | $108.20 | 9.7% |
| 81003 | Automated urinalysis test | Office | 2023 | 18 | 19 | $228.00 | $41.80 | 18.3% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 147 | 147 | $36,015 | $18,779 | 52.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 170 | 271 | $42,013 | $16,672 | 39.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 171 | 265 | $25,750 | $10,328 | 40.1% |
| 90694 | Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | Office | 2022 | 51 | 51 | $5,217 | $3,583 | 68.7% |
| G0008 | Administration of influenza virus vaccine | Office | 2022 | 57 | 57 | $3,192 | $1,598 | 50.1% |
| 83036 | Hemoglobin a1c level | Office | 2022 | 22 | 22 | $1,166 | $209.44 | 18.0% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2021 | 157 | 157 | $38,465 | $20,470 | 53.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 202 | 321 | $40,989 | $19,531 | 47.6% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 207 | 310 | $25,341 | $12,288 | 48.5% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 14 | 14 | $1,974 | $738.48 | 37.4% |
| 0003A | Fee covid-19 vac 1 booster | Office | 2021 | 19 | 19 | $1,235 | $725.23 | 58.7% |
| 0001A | Adm sarscov2 30mcg/0.3ml 1st | Office | 2021 | 12 | 12 | $780.00 | $458.04 | 58.7% |
| 93010 | Routine electrocardiogram (ekg) using at least 12 leads with interpretation and report | Office | 2021 | 18 | 20 | $460.00 | $122.81 | 26.7% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 200 | 326 | $41,290 | $14,992 | 36.3% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2020 | 103 | 103 | $25,235 | $11,715 | 46.4% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 205 | 328 | $26,953 | $10,120 | 37.5% |
About Dr. Mark Weiser, MD
Dr. Mark Weiser, MD is a Family Medicine healthcare provider based in Lexington, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/01/2006. The National Provider Identifier (NPI) number assigned to this provider is 1487621249.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mark Weiser, MD has received a total of $12,183 in payments from pharmaceutical and medical device companies, with $1,849 received in 2024. These payments were reported across 764 transactions from 42 companies. The most common payment nature is "Food and Beverage" ($12,047).
As a Medicare-enrolled provider, Weiser has provided services to 2,385 Medicare beneficiaries, totaling 3,297 services with total Medicare billing of $192,835. Data is available for 4 years (2020–2023), covering 29 distinct procedure/service records.
Ad
Practice Information
- Specialty Family Medicine
- Location Lexington, NC
- Active Since 03/01/2006
- Last Updated 11/10/2022
- Taxonomy Code 207Q00000X
- Entity Type Individual
- NPI Number 1487621249
Products in Payments
- Ozempic (Drug) $886.31
- VRAYLAR (Drug) $877.92
- JARDIANCE (Drug) $784.36
- FARXIGA (Drug) $591.80
- ELIQUIS (Drug) $503.37
- NURTEC ODT (Drug) $455.00
- UBRELVY (Drug) $444.66
- Linzess (Drug) $397.37
- MOUNJARO (Drug) $374.45
- TRELEGY ELLIPTA (Drug) $339.75
- Wegovy (Drug) $305.27
- TRULICITY (Drug) $297.98
- AIRSUPRA (Drug) $271.41
- ANORO (Drug) $237.95
- Yupelri (Drug) $210.13
- SOLIQUA 100/33 (Biological) $207.17
- SYMBICORT (Drug) $187.30
- Kerendia (Drug) $184.98
- Tresiba (Drug) $184.41
- CHANTIX (Drug) $157.67
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Medicine Doctors in Lexington
Dr. Keith Stokes, Md, MD
Family Medicine — Payments: $550,575
Family Medicine $550,575
John Richard, Md, MD
Family Medicine — Payments: $438,915
Family Medicine $438,915
Dr. Susan Neil, Md, MD
Family Medicine — Payments: $23,499
Family Medicine $23,499
William Crigler, Md, MD
Family Medicine — Payments: $18,109
Family Medicine $18,109
Dr. William Dacus, Md, MD
Family Medicine — Payments: $11,475
Family Medicine $11,475
Dr. William Korman, Md, MD
Family Medicine — Payments: $11,069
Family Medicine $11,069